

Date: September 6, 2023

To,To,BSE LimitedNational Stock Exchange of India LimitedPhiroze Jeejeebhoy TowersExchange Plaza, C-1, Block GDalal Street,Bandra Kurla ComplexMumbai – 400 001Bandra (E), Mumbai – 400 051Scrip Code: 543434Scrip Symbol: SUPRIYA

Dear Sir (s),

#### Sub: Business Responsibility and Sustainability Report for the Financial Year 2022-23

In compliance with Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the Business Responsibility and Sustainability Report of the Company for the Financial Year 2022-23.

Kindly take the above said information on your records.

Thanking you,

Yours faithfully, For Supriya Lifescience Limited

Shweta Singh Company Secretary & Compliance Officer Membership No.: A44973

Corporate office	: 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
	Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
	CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience .com Website: www.supriyalifescience.com
Factory	: A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.

GOVT. RECOGNISED EXPORT HOUSE







Business Responsibility and Sustainability Report

Annexure IV

### SECTION A- GENERAL DISCLOSURES

#### I. Details of the listed entity

- I-1. Corporate Identity Number (CIN) of the listed entity- L51900MH2008PLC180452
- I-2. Name of the listed entity- Supriya Lifescience Limited
- I-3. Year of incorporation- 2008
- I-4. Registered office address- 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai 400063, Maharashtra, India.

I-5. Corporate address - 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400063, Maharashtra, India.

I-6. E-mail - <u>cs@supriyalifescience.com</u>

- I-7. Telephone 022 40332727
- I-8. Website <u>www.supriyalifescience.com</u>
- I-9. Financial year for which reporting is being done April 1, 2022 March 31, 2023

I-10. Name of the Stock Exchange(s) where shares are listed - 1. BSE Limited ("BSE") 2. The National Stock Exchange of India Limited ("NSE")

I-11. Paid-up Capital - ₹160.97 million

I-12 Name and contact details (telephone, email address) of the person who may be contacted in case of any queries on the BRSR report.- Dr. Saloni Satish Wagh Whole Time Director Tel. No.: 022 4033 2727 Email id: <u>supriya@supriyalifescience.</u> <u>com</u>

I-13 Reporting boundary - Are the disclosures under this report made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements, taken together). - Standalone Basis

#### II. Products/services

II-14. Details of business activities (accounting for 90% of the turnover):

S. No.	Description of Main Activity	Description of Business Activity	% of Turnover of the entity
1	_	Manufacturing of Active Pharmaceutical	97.98%
	Ingredients	Ingredients	

II-15. Products/Services sold by the entity (accounting for 90% of the entity's Turnover):

S. No.	Product/Service	NIC Code	% of total Turnover contributed
1	Manufacturing & Sale of Active Pharmaceutical Ingredients	21001	97.98%

#### **III.** Operations

III-16. Number of locations where plants and/or operations/offices of the entity are situated:

Location	Number of Plants	Number of Offices	Total	
National	2	1	3	
International	0	0	0	



III-17. Markets served by the entity: a. Number of locations

Locations	Number
National (No. of States)	12
International (No. of Countries)	86

b. What is the contribution of exports as a percentage of the total turnover of the entity?

80%

c. A brief on types of customers

Our customer base is made up of innovators, various generic formulation suppliers and traders across various geographies.

#### IV. Employees

IV-18. Details as at the end of Financial Year: a. Employees and workers (including differently abled):

No	Particulars	Total(A)	Male		Female				
			No(B)	%(B/A)	No(C)	%(C/A)			
	Employees								
1	Permanent (D)	244	214	87.70%	30	12.30%			
2	Other than Permanent (E)	117	105	89.74%	12	10.26%			
3	Total employees (D + E)	361	319	88.37%	42	11.63%			
		Workers							
1	Permanent (F)	31	31	100.00%	0	0.00%			
2	Other than Permanent (G)	0	0	0.0%	0	0.0%			
3	Total Workers (F + G)	31	31	100.00%	0	0.00%			

IV-18. Details as at the end of Financial Year: b. Differently abled Employees and workers:

No	Particulars	Total(A)	Ma	Male		nale		
			No(B)	%(B/A)	No(C)	%(C/A)		
	Differently Abled Employees							
1	Permanent (D)	0	0	0.0%	0	0.0%		
2	Other than Permanent (E)	0	0	0.0%	0	0.0%		
3	Total differently abled employees (D + E)	0	0	0.0%	0	0.0%		
	Differen	tly Abled Wo	rkers					
1	Permanent (F)	0	0	0.0%	0	0.0%		
2	Other than Permanent (G)	0	0	0.0%	0	0.0%		
3	Total Workers (F + G)	0	0	0.0%	0	0.0%		

IV-19. Participation/Inclusion/Representation of women

	Total(A)	No. and percentage of Females	
		No(B)	%(B/A)
Board of Directors	10	4	40.00%
Key Management Personnel	3	1	33.33%

IV-20. Turnover rate for permanent employees and workers. (Disclose trends for the past 3 years)

	(Turnover rate in current FY)		(Turnover rate in previous FY)			(Turnover rate in the year prior to the previous FY)			
	Male	Female	Total	Male	Female	Total	Male	Female	Total
Permanent Employees	Not Available		Not Available		Not Available				
Permanent Workers	Not Available		Not Available		Not Available				

Remarks: We are currently not monitoring the turnover rates of employees broken down by employee category, however we will be implementing processes to start monitoring the same from the next year onwards.









#### V. Holding, Subsidiary and Associate Companies (including joint ventures)

V-21. (a) Names of holding / subsidiary / associate companies / joint ventures.

S. No.	Name of the holding / subsidiary / associate companies / joint ventures (A)	Indicate whether holding/ Subsidiary/ Associate/ Joint Venture	% of shares held by listed entity	Does the entity indicated at column A, participate in the Business Responsibility initiatives of the l isted entity? (Yes/No)
1	NIL	NIL	NIL	NIL

#### VI. CSR Details

VI-22. (i). Whether CSR is applicable as per section 135 of Companies Act, 2013: (Yes/No) - Yes

VI-22. (ii). Turnover (in ₹).- ₹4704.27 million

VI-22. (iii). Net worth (in ₹)- ₹6994.58 million

#### VII. Transparency and Disclosures Compliances

VII-23. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct:

Stakeholder	Grievance	FY 2022-2023			FY 2021-2022			
group from whom complaint is received	Redressal Mechanism in Place (Yes/No) (If Yes, then provide web-link for grievance redress policy)	Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks	Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks	
Communities	Yes	0	0	-	0	0	-	
Investors (other than shareholders)	Yes	0	0	-	0	0	-	
Shareholders	Yes	4	0	-	153	0	The Company had received Investor complaints pertaining to IPO allotment/ refunds during the financial year and all the complaints were resolved within the regulatory timeline. We have not received any significant complaints from stakeholders in the last financial year.	
Employees and workers	Yes	0	0	-	0	0	-	
Customers	Yes	0	0	-	0	0	-	
Value Chain partners	Yes	0	0	-	0	0	-	
Other (please specify)	-	-	-	-	-	-	-	



VII-24. Overview of the entity's material responsible business conduct issues. Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social matters that present a risk or an opportunity to your business, rationale for identifying the same, approach to adapt or mitigate the risk along-with its financial implications, as per the following format.

S. No.	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
1	Product Quality and Safety, and Data integrity	Risk	Our ability to meet patient demand, create value, and build trust with our stakeholders is highly dependent on product quality, safety, as well as data integrity. Any shortfalls in these critical areas can have severe consequences on our business and stakeholders	and build trust with our s is highly dependent quality, safety, as well grity. Any shortfalls in areas can have severe es on our business andimprovement and training programme with a focus on historically known gaps and challenges. Proactive identification of potential challenges through periodic	
2	Corporate Governance	Risk	Failure to comply with regulatory and statutory requirements can negatively impact our operations, our ability to raise funding, and the overall value of the company	Laying down effective policies and procedures to ensure compliance and prevent unlawful/ fraudulent activities. Continuous monitoring of compliances to avoid surprises and ensure timely remedial action.	Negative
3	Environmental Sustainability	Risk	The consequences of climate change, biodiversity loss, and over-use of natural resources have the potential to pose significant threats to business continuity and human safety. As such, there is a dire need for sustainable and proactive practices to mitigate risks and ensure a resilient future.	We are focused on incorporating practices to reduce our resource usage as much as possible. One of the ways that we do this is by using biofuels in our boilers, thus reducing GHG emissions during our operations.	Negative
4	Investment in R&D	Opportunity	We build, safeguard, and strengthen our research skills and stimulate innovative thinking across our organisation. This allows us to pursue operational excellence and create value for our stakeholders around the world, in accordance with our purpose of 'Caring for Life'.	-	Positive
5	Community Engagement	Opportunity	Community Engagement enables us to create shared value for our local communities, foster meaningful relationships, support social development, and contribute to the well-being of the areas in which we operate.	-	Positive

<b>ISCLOSURES</b>	
<b>IT AND PROCESS DISCLOSURE</b>	
AGEMENT AND	
CTION B- MANAC	
SECTIOI	

# Policy and management processes

1			I	1	I		I	1	
	6d	Yes	Yes	<u>www.</u> supriyalifescience. com	Yes	0 Z	ISO 9001:2015, CDSCO, USFDA, EDQM, NMPA	timelines.	
	P8	Yes	Yes	<u>www.</u> supriyalifescience <u>.</u> com	Yes	°Z	1	targets with defined	
	Р7	Yes	Yes	<u>www.</u> supriyalifescience. com	Yes	°Z	1	mitments, goals and	s are created.
	PG	Yes	Yes	<u>www.</u> supriyalifescience. com	Yes	°Z	1	our ESG performance, and accordingly we will be developing commitments, goals and targets with defined timelines.	The performance will be periodically monitored once the goals and targets are created.
	P5	Yes	Yes	<u>www.</u> supriyalifescience. com	Yes	°Z	1	accordingly we will	ally monitored once
	P4	Yes	Yes	<u>www.</u> supriyalifescience. com	Yes	°Z	1	G performance, and	nce will be periodic:
	P3	Yes	Yes	<u>www.</u> supriyalifescience. com	Yes	°Z	1		The performa
	P2	Yes	Yes	<u>www.</u> supriyalifescience. com	Yes	°Z	1	We are currently in the process of assessing	
-	P1	Yes	Yes	<u>www.</u> supriyalifescience. com	Yes	°Z	CDSCO, USFDA, EDQM, NMPA	We are cu	
	Disclosure Questions	a. Whether your entity's policy/ policies cover each principle and its core elements of the NGRBCs. (Yes/ No)	<ul> <li>b. Has the policy been approved by the Board? (Yes/No)</li> </ul>	c. Web Link of the Policies, if available	Whether the entity has translated the policy into procedures. (Yes / No)	Do the enlisted policies extend to your value chain partners? (Yes/No)	Name of the national and international codes/ certifications/labels/ standards (e.g. Forest Stewardship Council, Fairtrade, Rainforest Alliance, Trustea) standards (e.g. SA adopted by your entity and mapped to each principle.	Specific commitments, goals and targets set by the entity with defined timelines, if any.	Performance of the entity against the specific commitments, goals and targets along-with reasons in case the same are not met.
	Discle	-i		-	01	M	4	ы С	ý





#### Governance, leadership and oversight

7.	Statement by director responsible for the business responsibility report, highlighting	Dear Stakeholders,
	ESG related challenges, targets and achievements (listed entity has flexibility regarding the placement of this disclosure)	I am delighted to present Supriya Lifescience Ltd's first Business Responsibility and Sustainability Report. As a business driven by our mission of 'Caring for Life', empathy and a commitment to business responsibility is integral to our corporate ethos. Known for quality and operational excellence, our business has a global footprint that extends beyond 80+ countries. We encourage and stimulate innovative thinking, and are constantly looking to enhance the value that we create for our stakeholders. As a pharmaceutical company, we have a profound responsibility to society, our employees, our partners, and the environment. Being cognizant of this, we are now in the process of inculcating ESG into our business practices.
		While we are just starting out, we have already made some initial achievements. We are currently using biofuel in our operations, thus reducing our GHG footprint. We have a robust health and safety system, and have trained 100% of workers and 85% of employees with respect to proper health and safety protocols, in order to minimize incidents. Through our innovative approach, we are always looking at ways to improve access and affordability of our products. Our transparency, integrity and strong corporate governance practices make up the underlying foundation behind our ESG journey.
		We are committed to sustainable value creation for all our stakeholders, and are looking forward towards creating a more responsible and sustainable future.
		Regards,
8.	Details of the highest authority responsible for implementation and oversight of the Business Responsibility policy (ies).	Dr. Saloni Satish Wagh, Whole Time Director
9.	Does the entity have a specified Committee of the Board/ Director responsible for decision making on sustainability related issues? (Yes / No). If yes, provide details.	Dr. Saloni Satish Wagh, Whole Time Director

10. Details of Review of NGRBCs by the Company: Indicate whether review was undertaken by Director / Committee of the Board/ Any other Committee

Subject for Review		Indicate whether review was undertaken by Director / Committee of the Board/ Any other Committee						y (An Any o		-	-	-	
	P1	P1 P2 P3 P4 P5 P6 P7 P8 P9			P1	P2	P3	P4	P5	P6	P7	P8	P9
Performance against above policies and follow up action	Director						Annually						
Compliance with statutory requirements of relevance to the principles, and, rectification of any non- compliances				D	irecto	or				Annually			

Remarks: The Board assesses the policies of the Company at the required intervals. The Policies effective implementation is assessed and requisite amendments/modifications are adopted by the Board of Directors at their meeting.

11. Has the entity carried out independent assessment/ evaluation of the working of its policies by an external agency? (Yes/No). If yes, provide name of the agency.

Sr. no	P1	P2	P3	P4	P5	P6	P7	P8	P9
1									







12. If answer to question (1) above is No i.e. not all Principles are covered by a policy, reasons to be stated:

Questions	P1	P2	P3	P4	P5	P6	P7	P8	P9
The entity does not consider the Principles material to its business (Yes/No)				Not	Applic	able			
The entity is not at a stage where it is in a position to formulate and implement the policies on specified principles (Yes/No)									
The entity does not have the financial or/human and technical resources available for the task (Yes/No)									
It is planned to be done in the next financial year (Yes/No)									
Any other reason (please specify)									

#### SECTION C: PRINCIPLE WISE PERFORMANCE DISCLOSURE

# PRINCIPLE 1 Businesses should conduct and govern themselves with integrity, and in a manner that is Ethical, Transparent and Accountable.

#### **Essential Indicators**

El-1. Percentage covered by training and awareness programmes on any of the Principles during the financial year:

Segment	Total number of training and awareness programs held	Topics/principles covered under the training and its impact	Percentage of persons in respective category covered by the awareness programmes
Board of directors	2	Code of Conduct, Prevention of Sexual Harassment (POSH). This enables our Board to ensure that responsible, ethical and fair conduct is being adhered to throughout the company.	100%
Key Managerial personnel	3	Code of Conduct, Unpublished Price Sensitive Information (UPSI), Prevention of Sexual Harassment (POSH) to ensure that responsible, ethical and fair conduct is being adhered to throughout the company.	100%
Employees other than BoD and KMPs	3	Code of Conduct, Prevention of Sexual Harassment (POSH), Health & Safety. These trainings guide our employees with respect to their conduct in the workplace. In addition, Health and Safety trainings are held to ensure that the team is aware of the proper safety norms and protocols and ensure safety at all times.	80%
Workers	3	Code of Conduct, Prevention of Sexual Harassment (POSH), Health & Safety. These trainings guide our employees with respect to their conduct in the workplace. In addition, Health and Safety trainings are held to ensure that the team is aware of the proper safety norms and protocols and ensure safety at all times.	80%

EI-2. Details of fines / penalties /punishment/ award/ compounding fees/ settlement amount paid in proceedings (by the entity or by directors / KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the financial year, in the following format (Note: the entity shall make disclosures on the basis of materiality as specified in Regulation 30 of SEBI (Listing Obligations and Disclosure Obligations) Regulations, 2015 and as disclosed on the entity's website)

#### Monetary

Category	NGRBC Principle	Name of the regulatory/ enforcement agencies/ judicial institutions	Amount (In ₹)	Brief of the Case	Has an appeal been preferred? (Yes/No)
Penalty/ Fine	Nil	Nil	Nil	Nil	Nil
Settlement	Nil	Nil	Nil	Nil	Nil
Compounding fee	Nil	Nil	Nil	Nil	Nil



Non-Monetary

Category	NGRBC Principle	Name of the regulatory/ enforcement agencies/ judicial institutions	Brief of the Case	Has an appeal been preferred? (Yes/No)
Imprisonment	Nil	Nil	Nil	Nil
Punishment	Nil	Nil	Nil	Nil

EI-3. Of the instances disclosed in Question 2 above, details of the Appeal/ Revision preferred in cases where monetary or non-monetary action has been appealed.

Sr. no	Case Details	Name of the regulatory/ enforcement agencies/ judicial institutions
1	NA	NA

EI-4. Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, provide a web link to the policy.-

ANTI-BRIBERY AND ANTI-CORRUPTION POLICY : It is our policy to conduct all of our business in an honest and ethical manner. We take a zero-tolerance approach to bribery and corruption and are committed to acting professionally, fairly and with integrity in all our relationships and business dealings wherever we operate and to implementing and enforcing systems to counter bribery. We will uphold all laws relevant to countering bribery and corruption. We remain bound by the applicable Indian and international laws in respect of our conduct both at home and abroad.

EI-5. Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law enforcement agency for the charges of bribery/ corruption:

Category	(Current Financial Year)	(Previous Financial Year)
Directors	0	0
KMPs	0	0
Employees	0	0
Workers	0	0

EI-6. Details of complaints with regard to conflict of interest:

Category	Number (CY)	Remarks (CY)	Number (PY)	Remarks (PY)
Number of complaints received in relation to	Nil	_	Nil	-
issues of Conflict of Interest of the Directors				
Number of complaints received in relation to	Nil	-	Nil	-
issues of Conflict of Interest of the KMPs				

EI-7. Provide details of any corrective action taken or underway on issues related to fines / penalties / action taken by regulators/ law enforcement agencies/ judicial institutions, on cases of corruption and conflicts of interest.-

NIL

#### Leadership Indicators

LI-1. Awareness programmes conducted for value chain partners on any of the Principles during the financial year:

Sr. no	Total number of awareness programmes held	Topics / principles covered under the training	%age of value chain partners covered (by value of business done with such partners) under the awareness programmes
1	0	-	0

LI-2. Does the entity have processes in place to avoid/ manage conflict of interests involving members of the Board? (Yes/No) If Yes, provide details of the same.-

Yes, the Company has in place a 'Code of Conduct for Board Members and Senior Management' and a 'Related Party Transaction Policy', which are applicable to our board members. Transactions with the board members or any entity in which such board members are concerned or interested are required to be approved by the Audit Committee and the Board of Directors. In such cases, the interested directors abstain themselves from the discussions at the meeting. The weblink of the abovementioned policies are mentioned below: Code of Conduct for Board Members and Senior Management: <a href="https://supriyalifescience.com/wp-content/uploads/2021/09/Code-of-Conduct-for-Directors-and-Senior-Management.pdf">https://supriyalifescience.com/wp-content/uploads/2021/09/Code-of-Conduct-for-Directors-and-Senior-Management.pdf</a> Related Party Transaction Policy: <a href="https://supriyalifescience.com/wp-content/uploads/2021/09/Code-of-Conduct-for-Directors-and-Senior-Management.pdf">https://supriyalifescience.com/wp-content/uploads/2021/09/Code-of-Conduct-for-Directors-and-Senior-Management.pdf</a> Related Party Transaction Policy: <a href="https://supriyalifescience.com/wp-content/uploads/2021/09/Code-of-Conduct-for-Directors-and-Senior-Management.pdf">https://supriyalifescience.com/wp-content/uploads/2021/09/Code-of-Conduct-for-Directors-and-Senior-Management.pdf</a> Related Party Transaction Policy: <a href="https://supriyalifescience.com/wp-content/uploads/2022/06/Policy-on-Related-Party-Transactions.pdf">https://supriyalifescience.com/wp-content/uploads/2022/06/Policy-on-Related-Party-Transactions.pdf</a>





#### PRINCIPLE 2 Businesses should provide goods and services in a manner that is sustainable and safe

#### **Essential Indicators**

EI-1. Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve the environmental and social impacts of product and processes to total R&D and capex investments made by the entity, respectively.

Category	Current Financial Year	Previous Financial Year	Details of improvements in environmental and social impacts				
R&D	0.92	3.16	Improvement in Environmental impact parameters such as				
			Water, Air, Hazardous.				
Capex	99.08	96.84	To improvise the Emission absorption system, a healthy				
			and safe environment for workers				

EI-2.a. Does the entity have procedures in place for sustainable sourcing? (Yes/No)- Yes

EI-2.b. If yes, what percentage of inputs were sourced sustainably?- 60%

EI-3. Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the end of life, for (a) Plastics (including packaging) (b) E-waste (c) Hazardous waste and (d) other waste.-

- 1. Plastics (including packaging): The recycling and disposal of the plastics (including packaging) is carried out as per the Central Government rules and the provisions of the Plastic Waste Management Rules.
- 2. E-Waste: E-waste is disposed off through a registered recycler.
- 3. Hazardous Waste: Hazardous waste is disposed off to Treatment, storage, and disposal facility (TSDF) or authorized cement industries for further treatment and disposal or compressing.
- 4. Other Waste: Bio-medical waste is disposed off through authorized common bio-medical waste facilities

EI-4. Whether Extended Producer Responsibility (EPR) is applicable to the entity's activities (Yes / No). If yes, whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control Boards? If not, provide steps taken to address the same.-

Yes, As per CTO, Generated waste is sent to the authorized party on a quarterly basis and the same is reported to the Pollution Control Board through a manifest.

#### Leadership Indicators

LI-2. If there are any significant social or environmental concerns and/or risks arising from production or disposal of your products / services, as identified in the Life Cycle Perspective / Assessments (LCA) or through any other means, briefly describe the same along-with action taken to mitigate the same.

S.	Name of Product / Service	Description of the	Action Taken				
No.		risk / concern					
1	1. Chlorpheniramine Maleate.	GWP contribution	1. Improved technologies for the unit operations:				
	2. Salbutamol Sulphate.	in most of the units	Process intensification approach like integrating				
	3. Riboflavin	is due to indirect	unit operations and increasing process efficiency				
	4. Phosphate.	emission due to	of reactor can be explored.				
	5. Methyl Cobalamin.	electricity, and raw	2. Change of Equipment/ operating strategies:				
	6. Dex Chlorpheniramine	materials.	Green chemistry/ engineering principles				
			employed to optimize operating condition.				

LI-3. Percentage of recycled or reused input material to total material (by value) used in production (for manufacturing industry) or providing services (for service industry).

Indicate input material	Recycled or re-used input	material to total material		
	FY2022-2023	FY2021-2022		
Isopropyl Alcohol.	80%	75%		
O-Xylene	95%	80%		
Methanol	85%	80%		

LI-4. Of the products and packaging reclaimed at end of life of products, amount (in metric tons) reused, recycled, and safely disposed, as per the following format:

		FY2022-2	023	FY2021-2022			
	Re-Used Recycled Safely Disposed			Re-Used	Recycled	Safely Disposed	
Plastics (including packaging)	Nil	Nil	0.4 MT/A	Nil	Nil	0.3 MT/A	
E-waste	Nil	Nil	0.8 MT/A	Nil	Nil	Nil	
Hazardous waste	Nil	Nil	3.2 MT /A	Nil	Nil	6.96 MT /A	
Other waste	Nil	Nil	Nil	Nil	Nil	Nil	



## PRINCIPLE 3 Businesses should respect and promote the well-being of all employees, including those in their value chains

#### **Essential Indicators**

EI-1. a. Details of measures for the well-being of employees (Permanent Employees).

Category % of employees covered by												
	Total	Health in	surance	Accident i	Accident insurance M		Maternity benefits		Paternity benefits		Day Care facilities	
	(A)	Number (B)	% (B / A)	Number (C)	% (C / A)	Number (D)	% (D / A)	Number (E)	% (E / A)	Number (F)	% (F / A)	
					Permanen	t Employee	S					
Male	214	0	0.00%	188	87.85%	0	0.00%	0	0.00%	0	0.00%	
Female	30	0	0.00%	17	56.67%	30	100.00%	0	0.00%	0	0.00%	
Total	244	0	0.00%	205	84.02%	30	12.30%	0	0.00%	0	0.00%	
				Other	than perm	nanent Emp	loyees					
Male	105	0	0.00%	99	94.29%	0	0.00%	0	0.00%	0	0.00%	
Female	12	0	0.00%	9	75.00%	12	100.00%	0	0.00%	0	0.00%	
Total	117	0	0.00%	108	92.31%	12	10.26%	0	0.00%	0	0.00%	

EI-1.b. Details of measures for the well-being of workers. (Permanent Workers).

Category					% of er	nployees co	overed by				
	Total	Health insurance		Accident i	Accident insurance Maternity b		/ benefits	benefits Paternity benefits		Day Care facilities	
	(A)	Number (B)	% (B / A)	Number (C)			% (D / A)	Number (E)	% (E / A)	Number (F)	% (F / A)
Permanent Employees											
Male	31	0	0.00%	31	100.00%	0	0.00%	0	0.00%	0	0.00%
Female	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Total	31	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
				Other	than perm	anent Empl	oyees				
Male	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Female	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Total	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

EI-2. Details of retirement benefits, for Current FY and Previous Financial Year.

Benefits	No. of employees covered as a % of total employees. (CY)	No. of workers covered as a % of total workers. (CY)	Deducted and deposited with the authority (Y/N/N.A.). (CY)	No. of employees covered as a % of total employees. (PY)	No. of workers covered as a % of total workers. (PY)	Deducted and deposited with the authority (Y/N/N.A.). (PY)
PF	92%	100%	Yes	90%	0	Yes
Gratuity	100%	100%	Yes	100%	0	Yes
ESI	45%	0	Yes	1%	0	Yes
Others – please specify	0	0	-	0	0	-

EI-3. Are the premises / offices of the entity accessible to differently abled employees and workers, as per the requirements of the Rights of Persons with Disabilities Act, 2016? If not, whether any steps are being taken by the entity in this regard.-

No, our premises are currently not accessible to differently abled employees and workers.

EI-4. Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, provide a web-link to the policy.-







Yes, the same can be accessed at <u>https://supriyalifescience.com/investor-relation/corporate-governance/others/#1631718341575-b30ffa5c-fc01</u>

EI-5. Return to work and Retention rates of permanent employees and workers that took parental leave.

	Perman	ent employees	Permanent workers		
Gender	Return to work rate	eturn to work rate Retention rate		Retention rate	
Male	0	0	0	0	
Female	0	0	0	0	
Total	0	0	0	0	

EI-6. Is there a mechanism available to receive and redress grievances for the following categories of employees and worker? If yes, give details of the mechanism in brief.

Category	Yes/No (If Yes, then give details of the mechanism in brief)
Permanent Workers	Yes, covered under Grievance Redressal Policy
Other than Permanent Workers	Yes, covered under Grievance Redressal Policy
Permanent Employees	Yes, covered under Grievance Redressal Policy
Other than Permanent Employees	Yes, covered under Grievance Redressal Policy

EI-7. Membership of employees and worker in association(s) or Unions recognised by the listed entity:

Category		FY2022-2023			FY2021-2022	
	Total	No. of employees /	% (B	Total	No.of employees /	%(D
	employees	workers in respective	/ A)	employees	workers in respective	/ C)
	/ workers in category, who a		/ workers in		category, who are part	
	respective	of association(s) or		respective	of association(s)or	
	category (A)	Union(B)		category (C)	Union(D)	
Total Permanent	244	0	0%	204	0	0%
Employees						
- Male	214	0	0%	163	0	0%
- Female	30	0	0%	41	0	0%
Total Permanent	31	0	0%	33	0	0%
Workers						
- Male	31	0	0%	33	0	0%
- Female	0	0	0%	0	0	0%

EI-8. Details of training given to employees and workers:

Category		F	Y2022-202	.3				FY2021-2022	2		
	Total (A)	On Health meas	2	On Skill upgradation		Total (D)	On Health and safety measures		On Skill upgradation		
		No. (B)	% (B / A)	No. (C) % (C / A)			No. (E)	% (E / D)	No. (F)	% (F / D)	
	Employees										
Male	319	287	89.97%	0	0.00%	297	139	46.80%	0	0.00%	
Female	42	21	50.00%	0	0.00%	44	21	47.73%	0	0.00%	
Total	361	308	85.32%	0	0.00%	341	160	46.92%	0	0.00%	
					Workers						
Male	31	31	100.00%	0	0.00%	33	33	100.00%	0	0.00%	
Female	0	0	0.0%	0	0.0%	0	0	0.0%	0	0.0%	
Total	31	31	100.00%	0	0.00%	33	33	100.00%	0	0.0%	



Remarks: While approximately 80% of our employees and workers have been trained on topics such as POSH and Health and Safety, we don't have the breakdown by gender. However, we will be creating processes to ensure collection of this data in the near future.

Category		FY2022-2023			FY2021-2022			
	Total (A)	No. (B)	% (B / A)	Total (C)	No. (D)	% (D / C)		
Employees	_							
Male	319	319	100.00%	297	297	100.00%		
Female	42	42	100.00%	44	44	100.00%		
Total	361	361	100.00%	341	341	100.00%		
Workers								
Male	31	31	100.00%	33	33	100.00%		
Female	0	0	0.0%	0	0	0.0%		
Total	31	31	100.00%	33	33	100.00%		

EI-9. Details of performance and career development reviews of employees and workers

EI-10.a. Whether an occupational health and safety management system has been implemented by the entity? (Yes/ No). If yes, the coverage such system?-

Yes,

- i) Occupational health center provided, Pre- employment and periodically occupational health checkup of employees.
- ii) Fully equipped Ambulance van is in place.
- iii) Appointed medical officer.
- iv) Hygienic and adequate sanitary facilities to all employees.
- v) Occupational exposure monitoring.
- vi) Work permit system .
- vii) Mock drills,
- viii) HAZOP & risk assessment.
- ix) Safety audits.
- x) Fire Hydrant, suppression, Gas detection systems, etc placed in site.
- xi) Imparted employee's awareness training.

EI-10.b. What are the processes used to identify work-related hazards and assess risks on a routine and non-routine basis by the entity?-

Training and HAZOP & risk Assessment carried out by external and internal.

EI-10.c. Whether you have processes for workers to report the work related hazards and to remove themselves from such risks. (Y/N)-

Yes, i) Safety Violation Procedure, and Safety committee procedure is available, looking into complaint made on the likelihood of imminent dangers to the safety and health of the workers and suggests corrective measures. ii) additionally, suggestion/complaint box available.

EI-10.d. Do the employees/ worker of the entity have access to non-occupational medical and healthcare services? (Yes/ No)-

Yes, Carried out premedical, quarterly and annual medical checkup of all employees.

EI-11. Details of safety related incidents, in the following format:

Safety Incident/Number	Category	FY2022-2023	FY2021-2022
Lost Time Injury Frequency Rate (LTIFR) (per one million-person	Employees		
hours worked)	Workers		
Total recordable work-related injuries	Employees		
	Workers	Not Av	
No. of fatalities	Employees	Not Av	allable
	Workers		
High consequence work-related injury or ill-health (excluding	Employees		
fatalities)	Workers		

Remark: Currently we don't have data on the safety-related incidents, however we are working on developing processes to monitor this periodically.







EI-12. Describe the measures taken by the entity to ensure a safe and healthy work place. –

Periodically doing workplace, noise level monitoring, environmental monitoring, ergonomically hazardous monitoring, EI-13. Number of complaints on the following made by employees and workers

Category		FY2022-2023			FY2021-2022		
	Filed during the	Pending resolution at	Remarks	Filed during the	Pending resolution at	Remarks	
	year	the end of year		year	the end of year		
Working Conditions	0	0	None	0	0	None	
			received			received	
Health & Safety	0	0	None	0	0	None	
			received			received	

EI-14. Assessments for the year:

Category	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)				
Health and safety practices	100%				
Working Conditions	0				

Remarks: There were two visits done to assess the plants and offices.

EI-15. Provide details of any corrective action taken or underway to address safety-related incidents (if any) and on significant risks / concerns arising from assessments of health & safety practices and working conditions.-

No such corrective actions have needed to be undertaken regarding health and safety practices.

#### Leadership Indicators

LI-1. Does the entity extend any life insurance or any compensatory package in the event of death of (A) Employees (Y/N) (B) Workers (Y/N).-

Yes

# PRINCIPLE 4: Businesses should respect the interests of and be responsive to all its stakeholders

#### **Essential Indicators**

EI-1. Describe the processes for identifying key stakeholder groups of the entity.-

Internal and External group of Stakeholders have been identified. Presently, the given stakeholders group have the immediate impact on the operations and working of the Company. The primary stakeholders in Company include investors, board members, workers, clients, suppliers, the community, and regulators.

EI-2. List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder group.

S. No.	Stakeholder Group	Whether identified as Vulnerable & Marginalized Group (Yes/ No)	Channels of communication Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website), Other	Frequency of engagement (Annually/ Half yearly/ Quarterly / others – please specify)	Purpose and scope of engagement including key topics and concerns raised during such engagement
1	Investors/ Shareholders	No	Annual General Meeting, Stock Exchange Intimations, Annual Report, Email, Company Website	Annually/ Half yearly/ Quarterly/ Need-based	Share price appreciation, dividends, profitability and financial stability, corporate governance, regulatory compliance and overall Company performance.



S. No.	Stakeholder Group	Whether identified as Vulnerable & Marginalized Group (Yes/ No)	Channels of communication Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website), Other Pangagement (Annually/ Ha yearly/ Quart / others – ple specify)		Purpose and scope of engagement including key topics and concerns raised during such engagement
2	Employees	No	meetings efficience Long-te training respons commu		Innovation, Operational efficiency, improvement area, Long-term strategy plans, training and awareness, responsible marketing, brand communication, health, safety and engagement initiatives.
3	Customers	No	Website, Distributor/retailer/ direct customer/visits, customer plant visit, helpdesk, information on packaging,OngoingProduct quality ar responsiveness to aftersales service, guidelines/manuf		Product quality and availability, responsiveness to needs, aftersales service, responsible guidelines/manufacturing, life cycle assessment
4	Suppliers	No	Email & Website, In person meetings, con-call meetings, Vendor meets	Ongoing	Quality, timely delivery and payments, ESG consideration (sustainability, safety checks, compliances, ethical behavior), ISO standards, collaboration and digitalisation opportunities
5	Government and Regulators	No	E-mails and letters, Conferences,Industry forums,Regulatory filings,Meetings with officials, and Representations	On a need basis Regulatory filings, legislati ESG practices, framework for sustainability and beyo compliance, skill and capa building, employment, environmental measures, advocacy, timely contribut to local infrastructure, pro- engagement	
6	Communities	No	Physical meetings, Digital On a need basis Liveling relief, C on hea		Livelihood support, disaster relief, CSR activities with a focus on health, education, sanitation and infrastructure development.

#### Leadership Indicators

LI-1. Provide the processes for consultation between stakeholders and the Board on economic, environmental, and social topics or if consultation is delegated, how is feedback from such consultations provided to the Board.-

The Company management regularly interacts with key stakeholders i.e. investors, customers, suppliers, employees, etc. and has constantly prioritized the engagement with stakeholders as demonstrated by its corporate philosophy in conducting business with morality and responsibility towards society as a good citizen, implementing the code of conduct as a basis of work for all employees, employing the good corporate governance as a principle of management and exercising the sustainable development.







#### PRINCIPLE 5 Businesses should respect and promote human rights

#### **Essential Indicators**

EI-1. Employees and workers who have been provided training on human rights issues and policy(ies) of the entity, in the following format:

Category	FY2022-2023				FY2021-2022			
	Total (A)	No. of employees /	%(B / A)	Total No. of employees /		% (D / C)		
		workers covered (B)		(C)	workers covered (D)			
			Employees					
Permanent	244	244	100.00%	204	204	100.00%		
Other than	117	117	100.00%	137	137	100.00%		
permanent								
Total	361	361	100.00%	341	341	100.00%		
Employees								
			Workers					
Permanent	31	31	100.00%	33	33	100.00%		
Other than	0	0	0.0%	0	0	0.0%		
permanent								
Total Workers	31	31	100.00%	33	33	100.00%		

EI-2. Details of minimum wages paid to employees, in the following format:

Category FY2022-2023				FY2021-2022						
	Total (A)	Equa Minimur		More Minimur		Total (D)		al to m Wage		re than um Wage
		No. (B)	% (B /A)	No. ( C)	%(C / A)		No.(E)	% (E /D)	No.(F)	% (F /D)
				Em	ployees			·		
Permanent	244	0	0.00%	244	100.00%	204	0	0.00%	204	100.00%
Male	214	0	0.00%	214	100.00%	163	0	0.00%	163	100.00%
Female	30	0	0.00%	30	100.00%	41	0	0.00%	41	100.00%
Other than Permanent	117	0	0.00%	117	100.00%	137	0	0.00%	135	98.54%
Male	105	0	0.00%	105	100.00%	134	0	0.00%	134	100.00%
Female	12	0	0.00%	12	100.00%	3	0	0.00%	1	33.33%
				W	orkers					
Permanent	31	0	0.00%	31	100.00%	33	0	0.00%	33	100.00%
Male	31	0	0.00%	31	100.00%	33	0	0.00%	33	100.00%
Female	0	0	0.0%	0	0.0%	0	0	0.0%	0	0.0%
Other than Permanent	0	0	0.0%	0	0.0%	0	0	0.0%	0	0.0%
Male	0	0	0.0%	0	0.0%	0	0	0.0%	0	0.0%
Female	0	0	0.0%	0	0.0%	0	0	0.0%	0	0.0%

EI-3. Details of remuneration/salary/wages, in the following format:

		Male	Female		
	Number	Median remuneration/ salary/ wages of respective category	Number	Median remuneration/ salary/ wages of respective category	
Board of Directors (BoD)	2	66.35	3	14.89	
Key Managerial Personnel	2	18.79	1	1.00	
Employees other than BoD and KMP	319	0.28 (including workers)	34	0.33	
Workers	31	Please see above	0	0	

Remarks: Data is provided in ₹ million.



EI-4. Do you have a focal point (Individual/ Committee) responsible for addressing human rights impacts or issues caused or contributed to by the business? (Yes/No)-

No

EI-5. Describe the internal mechanisms in place to redress grievances related to human rights issues.-

At Supriya Lifescience Ltd., periodic visits are done by the Management to all of the facilities to ensure that all policies and procedures are being adhered to. We provide human rights training to our staff, and in addition, the premises are constantly monitored using CCTV cameras to ensure that there are no human rights violations occurring. Lastly, in case of any grievance, the staff approaches the management with respect to any grievances, and the management is responsible for redressal of the same.

EL & Number of	Complaints on	the fellowing made	by employees and workers:
EI-0. NUMBER OF	Complaints on	i the lottowing made	by employees and workers.

Category	FY2022-2023			FY2021-2022		
	Filed	Pending	Remarks	Filed	Pending	Remarks
	during the	resolution at		during the	resolution at	
	year	the end of year		year	the end of year	
Sexual Harassment	0	0	-	0	0	-
Discrimination at	0	0	-	0	0	-
workplace						
Child Labour	0	0	-	0	0	-
Forced Labour/	0	0	-	0	0	-
Involuntary Labour						
Wages	0	0	-	0	0	-
Other human rights	0	0	-	0	0	-
related issues						

EI-7. Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases.-

We are committed to ensuring a workplace that is safe for all of our staff and free from discrimination. Should there be any complaint filed with respect to discrimination or harassment, an Internal Complaints Committee oversees the process, in a way that ensures that the confidentiality of the Complainant is maintained throughout. Stringent protocols are followed to ensure that the complainant does not face any adverse consequences during the process or after.

EI-8. Do human rights requirements form part of your business agreements and contracts? (Yes/No)-

Yes

EI-9. Assessments for the year:

Category	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)
Child labour	100%
Forced/involuntary labour	100%
Sexual harassment	100%
Discrimination at workplace	100%
Wages	100%
Others – please specify	-

EI-10. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 9 above.-

No corrective actions were required to be undertaken as no significant risks/concerns arose from the assessment







# PRINCIPLE 6: Businesses should respect and make efforts to protect and restore the environment

#### **Essential Indicators**

EI-1. Details of total energy consumption (in Joules or multiples) and energy intensity.

Parameter	FY2022-2023	FY2021-2022
Total electricity consumption (A)	50892.3	38416.92
Total fuel consumption (B)	76566.810	60307.400
Energy consumption through other sources (C)	0	0
Total energy consumption (A+B+C)	127459.11	98724.32
Energy intensity per rupee of turnover (Total energy consumption/	27.09 GJ / Million	18.36 GJ / Million
turnover in rupees)		

EI-1. Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.-

No

EI-2. Does the entity have any sites / facilities identified as designated consumers (DCs) under the Performance, Achieve and Trade (PAT) Scheme of the Government of India? (Y/N) If yes, disclose whether targets set under the PAT scheme have been achieved. In case targets have not been achieved, provide the remedial action taken, if any.-

No

EI-3. Provide details of the following disclosures related to water, in the following format: Water withdrawal by source (in kilolitres)

Parameter	FY2022-2023	FY2021-2022
Water withdrawal by source (in kilolitres)		
(i) Surface water	0	0
(ii) Groundwater	0	0
(iii) Third party water	0	0
(iv) Seawater / desalinated water	0	0
(v) Others	84771	61592
Total volume of water withdrawal (in kilolitres) (i + ii + iii + iv + v)	84771	61592
Total volume of water consumption (in kilolitres)	84771	61592
Water intensity per rupee of turnover (Water consumed / turnover)	18.0200 KL /	11.4563 KL /
	Million	Million
Water intensity (optional) – the relevant metric may be selected by the entity. KL / of	Infinity	Infinity

EI-3. Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency-

No

EI-4. Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and implementation.-

No

EI- 5. Please provide details of air emissions (other than GHG emissions) by the entity, in the following format:

Parameter	Please specify unit	Current Financial Year	Previous Financial Year
NOx	Mg/Nm3	27.69	27.17
SOx	Kg/day	0.55	0.305
Particulate matter (PM)	Mg/Nm3	65.29	64.60
Persistent organic pollutants (POP)	_	-	-
Volatile organic compounds (VOC)	-	-	-
Hazardous air pollutants (HAP)	-	-	-
Others – please specify	-	-	-



EI-5. Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.-

No

EI-6. Provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its intensity, in the following format:

Parameter	Unit	FY 2022-2023	FY 2021-2022
Total Scope 1 emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)	tCO2e	490.206	315.257
Total Scope 2 emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)	tCO2e	11450.77	8643.81
Total Scope 1 and Scope 2 emissions per rupee	tCO2e / rupee of	2.5383 tCO2e /	1.6664 tCO2e /
of turnover	turnover	Million	Million

EI-6. Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.-

No

EI-7. Does the entity have any project related to reducing Green House Gas emission? If Yes, then provide details.-

No

EI-8. Provide details related to waste management by the entity, in the following format:

Parameter	FY2022-2023	FY2021-2022
Total Waste generated (in metric tonnes)		
Plastic waste (A)	8	6
E-waste(B)	2	1.2
Bio-medical waste (C)	0.05	0.01
Construction and demolition waste (D)	16	11
Battery waste (E)	0.75	0.2
Radioactive waste (F)	0	0
Other Hazardous waste.Please specify, if any. (G)	13.671	6.971
Other Non-hazardous waste generated (H). Please specify, if any.(Break-up by composition i.e. by materials relevant to the sector)	255	151.5
Total $(A + B + C + D + E + F + G + H)$	295.471	176.881

For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations (in metric tonnes)

Category of waste - Plastic		
(i) Recycled	NA	NA
(ii) Re-used	NA	NA
(iii) Other recovery operations	NA	NA
Total	NA	NA
Category of waste - E-Waste		
(i) Recycled	NA	NA
(ii) Re-used	NA	NA
(iii) Other recovery operations	NA	NA
Total	NA	NA
Category of waste - Bio-medical waste		
(i) Recycled	NA	NA
(ii) Re-used	NA	NA
(iii) Other recovery operations	NA	NA
Total	NA	NA







Parameter	FY2022-2023	FY2021-2022
Category of waste - Construction and demolition waste		
(i) Recycled	NA	NA
(ii) Re-used	NA	NA
(iii) Other recovery operations	NA	NA
Total	NA	NA
Category of waste - Battery waste		
(i) Recycled	NA	NA
(ii) Re-used	NA	NA
(iii) Other recovery operations	NA	NA
Total	NA	NA
Category of waste - Radioactive waste		
(i) Recycled	0	0
(ii) Re-used	0	0
(iii) Other recovery operations	0	0
Total	0	0
Category of waste - Other Hazardous waste		
(i) Recycled	0	0
(ii) Re-used	0	0
(iii) Other recovery operations	13.671	6.971
Total	13.671	6.971
Category of waste - Other Non-Hazardous waste		
(i) Recycled	NA	NA
(ii) Re-used	NA	NA
(iii) Other recovery operations	NA	NA
Total	NA	NA
For each category of waste generated, total waste disposed by n	ature of disposal method (in n	netric tonnes)
Category of waste - Plastic		
(i) Incineration	NA	NA
(ii) Landfilling	NA	NA
(iii) Other disposal operations	NA	NA
Total	NA	NA
Category of waste - E-Waste		
(i) Incineration	NA	NA
(ii) Landfilling	NA	NA
(iii) Other disposal operations	NA	NA
Total	NA	NA
Category of waste - Bio-medical Waste		
(i) Incineration	NA	NA
(ii) Landfilling	NA	NA
(iii) Other disposal operations	NA	NA
Total	NA	NA
Category of waste - Construction and demolition waste		
(i) Incineration	NA	NA
(ii) Landfilling	NA	NA
(iii) Other disposal operations	NA	NA



Parameter	FY2022-2023	FY2021-2022
Category of waste - Battery		
(i) Incineration	NA	NA
(ii) Landfilling	NA	NA
(iii) Other disposal operations	NA	NA
Total	NA	NA
Category of waste - Radioactive		
(i) Incineration	0	0
(ii) Landfilling	0	0
(iii) Other disposal operations	0	0
Total	0	0
Category of waste - Other Hazardous waste. Please specif	y, if any	
(i) Incineration	NA	NA
(ii) Landfilling	NA	NA
(iii) Other disposal operations	NA	NA
Total	NA	NA
Category of waste - Other Non-hazardous waste generate	ed	
(i) Incineration	NA	NA
(ii) Landfilling	NA	NA
(iii) Other disposal operations	NA	NA
Total	NA	NA

#### Remarks: NA: Not Available

Hazardous Waste Breakup: 1. Distillation residue (MT/A): FY 2022-23: 4.220 MT, FY 2021-22: 3.437 MT 2. ETP Sludge(MT/A): FY 2022-23: 7.558 MT, FY 2021-22: 2.902 MT 3. Spent Carbon (MT/A): FY 2022-23: 1.893 MT, FY 2021-22: 0.632 MT Other Non-Hazardous Waste Breakup: 1. Boiler Ash: FY 2022-23: 250 MT, FY 2021-22: 150 MT 2. Metal Scrap: FY 2022-23: 5 MT, FY 2021-22: 1.5 MT

EI-8. Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.-

No

EI-9. Briefly describe the waste management practices adopted in your establishments. Describe the strategy adopted by your company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices adopted to manage such wastes.-

Waste is generated by the department respectively and reported to the EHS department. The EHS department categorizes its category and sends it safely to the authorized vendor. In order to reduce the usage of hazardous and toxic chemicals in our products and processes, we do the following: Avoid mixing hazardous waste with non-hazardous waste, Limiting quantities purchased, Inventory management and control, Good housekeeping practices, Training, Segregation, Eliminating unknown chemicals, Recycling, Distillation.

EI-10. If the entity has operations/offices in/around ecologically sensitive areas (such as national parks, wildlife sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where environmental approvals / clearances are required, please specify details in the following format:

S. No.	Location of operations/offices	Type of operations	Whether the conditions of environmental approval / clearance are being complied with? (Y/N) If no, the reasons thereof and corrective action taken, if any.
1	Supriya Lifescience LTD. Plot No A5/1, 5/2,5/3,6/1,6/2,6/3, lote parshuram Ind Area Tal-Khed, Dist Ratnagiri	API- batch process	Yes







EI-11. Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in the current financial year:

S. No.	Name and brief details of project	EIA Notification No.	Date	Whether conducted by independent external agency (Yes / No)	Results communicated in public domain (Yes / No)	Relevant Web link
1	Under B2 Category as per MOEFCC Notification: SO no 1223 (E) March 27 2020	SIA/MH/IND2/151852/2020	March 27 2020	Yes	Yes	-

EI-12. Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India; such as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment protection act and rules thereunder (Y/N). If not, provide details of all such non-compliances, in the following format:

S. No.	Specify the law / regulation / guidelines which was not complied with	Provide details of the non- compliance	Any fines / penalties / action taken by regulatory agencies such as pollution control boards or by courts	Corrective action taken, if any
1	Nil	Nil	Nil	Nil

#### Leadership Indicators

LI-1. Provide break-up of the total energy consumed (in Joules or multiples) from renewable sources, in the following format:

Parameter	FY2022-2023	FY2021-2022
From renewable sources		
Total electricity consumption (A)	0	0
Total fuel consumption (B)	0	0
Energy consumption through other sources ( C )	0	0
Total energy consumed from renewable sources (A+B+C)	0	0
From non-renewable sources		
Total electricity consumption (D)	50892.3	38416.92
Total fuel consumption (E)	76566.810	60307.400
Energy consumption through other sources (F)	0	0
Total energy consumed from non Renewable sources (D+E+F)	127459.11	98724.32

LI-2. Provide the following details related to water discharged: Water discharge by destination and level of treatment (in kilolitres)

Parameter			FY2022-2023	FY2021-2022
Water discharge by destination and level of treatmen	ıt (in kilolitre	es)		
(i) To Surface water				
- No treatment			0	0
With treatment – please specify level of treatment	CY:	PY:	0	0
(ii) To Groundwater				
- No treatment			0	0
With treatment – please specify level of treatment	CY:	PY:	0	0
(iii) To Seawater				
- No treatment			0	0
With treatment – please specify level of treatment	CY:	PY:	0	0
(iv) Sent to third-parties				
- No treatment			0	0
With treatment – please specify level of treatment	CY:	PY:	0	0
(v) Others				
- No treatment			0	0
With treatment – please specify level of treatment	CY:	PY:	67816	49273
Total water discharged (in kilolitres)			67816	49273



# PRINCIPLE 7 Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent

#### Essential Indicators

El-1.a. Number of affiliations with trade and industry chambers/ associations.-

5

EI-1.b. List the top 10 trade and industry chambers/ associations (determined based on the total members of such body) the entity is a member of/ affiliated to.

S. No.	Name of the trade and industry chambers/associations	Reach of trade and industry chambers/ associations (State/National)
1	(a) Chemicals Export Promotion Council (CHEMEXCIL)	National
	(b) Pharmaceutical Export Promotion Council of India (PHARMEXCIL)	National
	(c) Federation of Indian Export Organisations (FIEO)	National
	(d) Maharashtra Chamber of Commerce, Industry & Agriculture (MACCIA)	State
	(e) IMC Chamber of Commerce and Industry	National

EI-2. Provide details of corrective action taken or underway on any issues related to anti-competitive conduct by the entity, based on adverse orders from regulatory authorities.

S. No.	Name of authority	Brief of the case	Corrective action taken
1	Nil	Nil	Nil

# PRINCIPLE 8 Businesses should promote inclusive growth and equitable development

#### **Essential Indicators**

EI-1. Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, in the current financial year.

S. No.	Name and brief details of project	SIA Notification No.	Date of notification	Whether conducted by independent external agency (Yes / No)	Results communicated in public domain (Yes / No)	Relevant Web link
1	NA	NA	NA	NA	NA	NA

EI-2. Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is being undertaken by your entity, in the following format:

N	S. Io.	Name of Project for which R&R is ongoing	State	District	No. of Project Affected Families (PAFs)	% of PAFs covered by R&R	Amounts paid to PAFs in the FY (In ₹)
	1	NA	NA	NA	NA	NA	NA

EI-3. Describe the mechanisms to receive and redress grievances of the community.-

There is a Point of Contact from the CSR team whom the community can go to with respect to any grievances. The POC visits the community on a regular basis for monitoring of CSR projects, and also conducts stakeholder engagement with the community members.

EI-4. Percentage of input material (inputs to total inputs by value) sourced from suppliers:

Category	Current Financial Year	Previous Financial Year
Directly sourced from MSMEs/ small producers	0	0
Sourced directly from within the district and neighbouring	0	0
districts		

Remark: We currently don't have data on this, but will be developing processes to collect data for the same in the near future.







PRINCIPLE 9 Businesses should engage with and provide value to their consumers in a responsible manner

#### **Essential Indicators**

EI-1. Describe the mechanisms in place to receive and respond to consumer complaints and feedback.-

Customer complaints are handled by cross functional team involving QA and R&D along with Marketing team. After investigation, the correct action plan is discussed with the customers to prevent further occurrence. Regular feedback is taken from customers for Quality compliance and also overall service levels.

EI-2. Turnover of products and/ services as a percentage of turnover from all products/service that carry information about:

Category	As a percentage to total turnover
Environmental and social parameters relevant to the product	5
Safe and responsible usage	5
Recycling and/or safe disposal	0

#### EI-3. Number of consumer complaints in respect of the following:

Category		FY2022-2023		FY2021-2022		
	Received	Pending	Remarks	Received	Pending	Remarks
	during the	resolution at		during the	resolution at	
	year	end of year		year	end of year	
Data privacy	0	0	Nil	0	0	Nil
Advertising	0	0	Nil	0	0	Nil
Cyber-security	0	0	Nil	0	0	Nil
Delivery of essential	0	0	Nil	0	0	Nil
services						
Restrictive Trade	0	0	Nil	0	0	Nil
Practices						
Unfair Trade Practices	0	0	Nil	0	0	Nil
Other	0	0	Nil	0	0	Nil

EI-4. Details of instances of product recalls on account of safety issues:

Category	Number	Reasons for recall
Voluntary recalls	0	Nil
Forced recalls	0	Nil

EI-5. Does the entity have a framework/ policy on cyber security and risks related to data privacy? (Yes/No) If available, provide a web-link of the policy.-

Yes, the same can be accused at <u>https://supriyalifescience.com/investor-relation/corporate-governance/others/#1631718341575-b30ffa5c-fc01</u>

EI-6. Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of essential services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; penalty / action taken by regulatory authorities on safety of products / services.-

As no complaints were received, thus no corrective actions were needed to be undertaken. However, we are always working on improving our processes.

Leadership Indicators

LI-1. Channels / platforms where information on products and services of the entity can be accessed (provide web link, if available).- Company Website (<u>https://supriyalifescience.com/</u>)

LI-2. Steps taken to inform and educate consumers about safe and responsible usage of products and/or services.-Product Safety Information is given at the time of Dispatch of goods.

LI-4. Does the entity display product information on the product over and above what is mandated as per local laws? (Yes/No/Not Applicable) If yes, provide details in brief. Did your entity carry out any survey with regard to consumer satisfaction relating to the major products / services of the entity, significant locations of operation of the entity or the entity as a whole? (Yes/No)-

Customer satisfaction index is maintained by quality department as part of commercial excellence.